AZD4625
AZD4625 is an orally active, selective irreversible, covalent allosteric GTPase KRASG12C inhibitor with an IC50 of 3 nM. AZD4625 can inhibit the MAPK pathway (with decreased pCRAF, pMEK, and pERK) and the PI3K pathway (with decreased pAKT and pS6), and induce cell apoptosis. AZD4625 has no binding and inhibition of wild-type RAS or isoforms carrying non-KRASG12C mutations. AZD4625 can be used for the study of KRASG12C mutant non-small cell lung cancer[1][2].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; p38 MAPK; PI3K; Ras
Type
Reference compound
Related Pathways
Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/azd4625.html
Purity
99.52
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C=CC(N1C[C@H]2N(C3=C4C(OCC2)=C(Cl)[C@@]([C@@]5=C(F)C=CC=C5O)=C(F)C4=NC=N3)C[C@H]1C)=O
Molecular Formula
C24H21ClF2N4O3
Molecular Weight
486.90
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
K-Ras
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Colloidal Gold Conjugated Helix pomatia Lectin (Edible Snail) -HPA-, 30nm
